Life Sciences & Health Care

Insights and learnings for Japanese life sciences organizations that are globalizing to fulfill growth ambitions. Driven by domestic economic and industry-specific challenges, many Japan-headquartered life sciences organizations are looking at greater globalization as a catalyst for growth and innovation. This report highlights this trend via executive interviews across Japanese life sciences (LS) organizations, non-Japanese LS organizations, and cross-industry Japanese organizations.

Our 15th year analysing the forecast average internal rate of return (IRR) for the top 20 biopharma companies, reveals a second year of growth to 5.9 per cent in 2024. Discover more.

This report highlights exponential technology, enhancing efficiency, productivity, and patient engagement as the key priorities of health system leaders in 2025.

Despite industry uncertainties, life sciences execs expect their organizations to adapt, grow, and generate value

Welcome to the fourth of a series of life sciences and healthcare predictions reports, comprising ten predictions exploring how the world could look in 2030, what it might feel like for different stakeholders in the health ecosystem, the evidence today that informs our views of tomorrow and how AI technologies, specifically GenAI, might help bring the future closer.

The Future of Health Series is a dynamic collection of webcasts designed to spark conversations and drive meaningful change across the health care landscape.

In this report, Project HOPE and Deloitte US have brought together frontline health care workers, program leaders, health system advisors, policy and advocacy professionals, community leaders, and strategic relationships to collaborate on potential solutions for enhancing climate resilience.

Platform businesses are rewiring the traditional value chain. In nearly every industry, well-thought-out platform businesses typically beat traditional businesses because of superior unit economics and network effects.

Deloitte's Electronic Health Record (EHR) solution helps health systems execute digital transformation that shifts legacy models into modern best practices anchored on elevating the human experience.

The COVID-19 pandemic exposed a glaring disparity in global vaccine access. The World Economic Forum (WEF) and Deloitte have been collaborating to tackle this challenge by advocating for regionalized vaccine manufacturing ecosystems. This approach aims to revolutionize vaccine production and distribution, promoting equity and resilience in the face of future health crises.

From digital health to biotech and from digital therapeutics to health care IT innovations, there’s a community and a conversation about it at HLTH Europe event.

Measuring the return from pharmaceutical innovation – 14th edition

The critical success factors identified in 2020 remain paramount. But now stakeholders need to act on the lessons learned to strengthen the collective ability to respond to or—better yet—proactively address the existing global health issues.

A Deloitte and World Economic Forum report